Centre for Pharmacoepidemiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Clin Epidemiol. 2010 Oct 21;2:205-7. doi: 10.2147/CLEP.S10426.
Depression during pregnancy occurs frequently and selective serotonin reuptake inhibitors (SSRIs) are often the drug of choice when treating pregnant women. Most published studies found no increased risks of congenital malformations in association with SSRIs, but there are reports of various malformations for SSRIs as a group and for specific SSRIs. To assess potential adverse effects of SSRIs as one group may be questioned because of their dissimilarities and very large datasets are needed when studying specific SSRIs. The national health and population registers in the Nordic countries offer excellent opportunities to assess long term effects of exposure during fetal life. As each of the Nordic countries is small, collaborative studies including information from all the Nordic countries are warranted to fully understand risks associated with exposure to antidepressants in fetal life.
怀孕期间抑郁症很常见,在治疗孕妇时,选择性 5-羟色胺再摄取抑制剂(SSRIs)通常是首选药物。大多数已发表的研究发现,SSRIs 与先天性畸形风险增加无关,但也有报道称 SSRIs 整体以及特定 SSRIs 存在各种畸形。评估 SSRIs 作为一个药物组的潜在不良影响可能会受到质疑,因为它们之间存在差异,而且在研究特定 SSRIs 时需要非常大的数据集。北欧国家的国家健康和人口登记提供了评估胎儿期暴露潜在影响的绝佳机会。由于每个北欧国家都很小,因此需要进行包括所有北欧国家信息的合作研究,以充分了解与胎儿期暴露于抗抑郁药相关的风险。